Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency at the European Respiratory Society Congress 2026 Life Science Investing
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen Life Science Investing
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care Life Science Investing
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms Life Science Investing
Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.'s Board of Directors Life Science Investing
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress Life Science Investing
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company Life Science Investing
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences Life Science Investing
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business Life Science Investing
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
